Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

Autor: Zhang, Xiaotian, Liang, Han, Li, Ziyu, Xue, Yingwei, Wang, Yanong, Zhou, Zhiwei, Yu, Jiren, Bu, Zhaode, Chen, Lin, Du, Yian, Wang, Xinbao, Wu, Aiwen, Li, Guoli, Su, Xiangqian, Xiao, Gang, Cui, Ming, Wu, Dan, Chen, Li, Wu, Xiaojiang, Zhou, Yanbing, Zhang, Lianhai, Dang, Chengxue, He, Yulong, Zhang, Zhongtao, Sun, Yihong, Li, Yong, Chen, Huanqiu, Bai, Yuxian, Qi, Changsong, Yu, Peiwu, Zhu, Guanbao, Suo, Jian, Jia, Baoqing, Li, Leping, Huang, Changming, Li, Fei, Ye, Yingjiang, Xu, Huimian, Wang, Xin, Yuan, Yannan, E, Jian-Yu, Ying, Xiangji, Yao, Chen, Shen, Lin **, Ji, Jiafu *
Zdroj: In The Lancet Oncology August 2021 22(8):1081-1092
Databáze: ScienceDirect